Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?

Research output: Contribution to journalReview article

27 Scopus citations

Abstract

5-HT3 antagonists are effective treatments for chemotherapy-induced emesis and diarrhoea and urgency and pain associated with irritable bowel syndrome. Reports of ischaemic colitis led to restricted use of the approved drug, alosetron. This article briefly reviews the controversial information from epidemiology and adverse reaction reports and addresses the experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment. The author reviews the potential factors based involved in the ischaemic colitis and ways in which this class of compound may influence those factors based on experimental evidence, including the literature on any vascular effects of these agents. Finally, the article addresses the theoretical basis for the constipation as a predisposing factor for the development of ischaemic colitis. The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalNeurogastroenterology and Motility
Volume19
Issue number2
DOIs
StatePublished - Feb 2007

Keywords

  • Alosetron
  • Cilansetron
  • Colon
  • Constipation
  • Ischaemia
  • Mucosa

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology

Fingerprint Dive into the research topics of 'Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT<sub>3</sub> antagonist treatment?'. Together they form a unique fingerprint.

  • Cite this